{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:03:53Z","timestamp":1790352233006,"version":"4.1.0"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Anifrolumab (ANI), a type I interferon receptor antagonist, has demonstrated clinical efficacy in systemic lupus erythematosus (SLE). However, its effects on serological markers commonly used to assess disease activity in clinical practice remain uncertain. This study evaluated changes in complement and autoantibody levels in SLE patients treated with ANI under routine care conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a single-center retrospective analysis of SLE patients receiving \u22653 ANI infusions over a 12-month period. Clinical and serological data, including complement (C3c, C4), anti-double-stranded DNA (anti-dsDNA) antibodies, prednisone dose, and SLE Disease Activity Index 2000 (SLEDAI-2K) scores, were analyzed using mixed-effects modeling (REML). Correlations between changes in clinical SLEDAI-2K (excluding serological components) and serological markers were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen patients (84.6% female, median age 53 years) were included. The median baseline SLEDAI-2K was 10, and 76.9% exhibited abnormal complement and\/or anti-dsDNA levels. Over the treatment course (median 12 infusions), 76.9% of patients improved clinically, with a mean SLEDAI-2K reduction of 3.77 \u00b1 2.78 points (p &amp;lt; 0.001). Prednisone doses decreased in 38.5% of cases. Complement (C3c, p = 0.25; C4, p = 0.10) and anti-dsDNA levels (p = 0.12) remained largely unchanged. No correlations were observed between clinical SLEDAI-2K improvement and serological parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Anifrolumab therapy led to significant clinical improvement without corresponding serological changes, suggesting that traditional biomarkers may not adequately reflect therapeutic response. Monitoring under ANI should therefore emphasize clinical rather than serological parameters. These findings have implications for interpreting composite disease activity indices incorporating immunological markers in SLE management depending on the mechanism of action of a particular treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1737281","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:53:01Z","timestamp":1773211981000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Complement and autoantibody levels under anifrolumab therapy in SLE: implications for clinical practice"],"prefix":"10.3389","volume":"17","author":[{"given":"Jan-Gerd","family":"Rademacher","sequence":"first","affiliation":[{"name":"Department of Nephrology and Rheumatology, University Medical Center G\u00f6ttingen","place":["G\u00f6ttingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Tampe","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, University Medical Center G\u00f6ttingen","place":["G\u00f6ttingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Korsten","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, University Medical Center G\u00f6ttingen","place":["G\u00f6ttingen, Germany"]},{"name":"Department of Rheumatology and Clinical Immunology, St. Josef-Stift Sendenhorst","place":["Sendenhorst, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"B3","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-025-01646-8","article-title":"Annual report 2025 from the National Database of the Regional Collaborative Rheumatology Centers in Germany","volume":"84","author":"Albrecht","year":"2025","journal-title":"Z Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I interferon in the pathogenesis of lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e000270","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon pathway in SLE: one key to unlocking the mystery of the disease","volume":"6","author":"R\u00f6nnblom","year":"2019","journal-title":"Lupus Sci Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheumatic Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roae111","article-title":"Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trial","volume":"35","author":"Tanaka","year":"2025","journal-title":"Modern Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/art.24699","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis Rheumatism"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309350752","article-title":"Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following Rituximab treatment in systemic lupus erythematosus","volume":"19","author":"Tew","year":"2010","journal-title":"Lupus"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e000261","DOI":"10.1136\/lupus-2018-000261","article-title":"Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus","volume":"5","author":"Riggs","year":"2018","journal-title":"Lupus Sci Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-023-01238-2","article-title":"Clinical pharmacokinetics, pharmacodynamics, and immunogenicity of anifrolumab","volume":"62","author":"Tang","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/art.42862","article-title":"Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to janus kinase inhibitors versus adalimumab: A nationwide cohort study","volume":"76","author":"Hoisnard","year":"2024","journal-title":"Arthritis Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1737281\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:53:02Z","timestamp":1773211982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1737281\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":13,"alternative-id":["10.3389\/fimmu.2026.1737281"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1737281","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"article-number":"1737281"}}